KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Operations (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Cash from Operations data on record, last reported at 130315000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 10.36% year-over-year to 130315000.0; the TTM value through Dec 2025 reached 339992000.0, up 15.21%, while the annual FY2025 figure was 339992000.0, 15.21% up from the prior year.
  • Cash from Operations reached 130315000.0 in Q4 2025 per AMRX's latest filing, up from 118450000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 148128000.0 in Q1 2021 and bottomed at 125521000.0 in Q2 2022.
  • Average Cash from Operations over 5 years is 64379400.0, with a median of 83091500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 141.7% in 2022, then skyrocketed 683.13% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 63261000.0 in 2021, then crashed by 136.82% to 23292000.0 in 2022, then surged by 683.13% to 135823000.0 in 2023, then dropped by 13.06% to 118078000.0 in 2024, then increased by 10.36% to 130315000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 130315000.0 in Q4 2025, 118450000.0 in Q3 2025, and 83819000.0 in Q2 2025.